Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | Biomarker | disease | BEFREE | <i>ERBB</i> gene family mutations, which are present in 7% of our HER2+ breast cancer cohort, may have the potential to alter cellular behaviour and the efficacy of HER- and PI3K-inhibition. | 30023006 | 2018 | ||||
|
0.080 | AlteredExpression | disease | BEFREE | We, therefore, aimed to find a better read-out of activation of the PI3K and MAPK pathways in ER+/HER2- breast cancer. | 30287915 | 2018 | ||||
|
0.080 | Biomarker | disease | BEFREE | Combination therapies with phosphoinositide 3-kinase (PI3K) inhibitors and trastuzumab (anti-human epidermal growth factor receptor [HER]2/neu antibody) are effective against HER2+ breast cancer. | 29721370 | 2018 | ||||
|
0.080 | Biomarker | disease | BEFREE | This review focuses on the recent reports of the essential role of PI3K/Akt/mTOR and CDK4/6/RB pathways in ER+ HER2- breast cancer. | 29086897 | 2018 | ||||
|
0.080 | Biomarker | disease | BEFREE | The Neoadjuvant PI3K inhibition in HER2 OverExpressing Breast cancEr (NeoPHOEBE) trial evaluated the efficacy and safety of buparlisib, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, plus trastuzumab and paclitaxel as neoadjuvant treatment for human epidermal growth factor receptor-2 positive (HER2+) breast cancer. | 28923573 | 2017 | ||||
|
0.080 | Biomarker | disease | BEFREE | Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. | 29020035 | 2017 | ||||
|
0.080 | AlteredExpression | disease | BEFREE | Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. | 24451154 | 2014 | ||||
|
0.080 | Biomarker | disease | BEFREE | Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor. | 22737248 | 2012 |